证券代码：600617 证券简称：国新能源 公告编号：2026-003 山西省国新能源股份有限公司关于股东减持计划时间届满暨减持结果公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏， 并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ● 持股5%以上股东及其一致行动人持股的基本情况 截至本公告披露日，太原市宏展房地产开发有限公司（以下简称"宏展房产"）及其一致行动人兰旭合计 持有山西省国新能源股份有限公司（以下简称"公司"）A股股份177,769,858股，占公司总股本的 9.2147%。其中宏展房产持有公司A股股份177,615,858股，占公司总股本的9.2067%。 ● 减持计划的实施结果情况 一、减持主体减持前基本情况 ■ 上述减持主体存在一致行动人： ■ 二、减持计划的实施结果 (一)大股东因以下事项披露减持计划实施结果： 披露的减持时间区间届满 ■ (二)本次减持是否遵守相关法律法规、本所业务规则的规定 √是 □否 公司于2025年10月24日在上海证券交易所网站（www.sse.com.cn）披露了《山西省国新能源股份有限公 司股东减 ...

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：603258 证券简称：电魂网络 公告编号：2026-005 杭州电魂网络科技股份有限公司 关于持股5%以上股东权益变动触及1%刻度、提前终止减持计划暨减持股份结果公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏， 并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ● 大股东持股的基本情况 本次减持股份计划实施前，杭州电魂网络科技股份有限公司（以下简称"公司"）董事、副总经理胡玉彪 先生持有公司股份19,300,000股，占公司股份总数的7.91%。 ● 减持计划的实施结果情况 公司于2025年12月6日披露了《股东减持股份计划公告》（公告编号：2025-041），胡玉彪先生计划通 过集中竞价交易方式减持公司股份不超过2,438,967股，即不超过公司总股本的1.00%。 2026年2月13日，公司收到胡玉彪先生发来的《关于权益变动比例触及1%、提前终止减持计划暨减持股 份结果的告知函》，胡玉彪于2026年1月5日至2026年2月13日期间，通过集中竞价方式减持公司股份 2,400,000 ...

登录新浪财经APP 搜索【信披】查看更多考评等级 股票代码：603429 股票简称：集友股份 公告编号：2026-006 安徽集友新材料股份有限公司 关于公司股票可能被实施退市风险警示的 根据《股票上市规则》第9.3.2条第（一）项规定："（一）最近一个会计年度经审计的利润总额、净利 润或者扣除非经常性损益后的净利润孰低者为负值且营业收入低于3亿元，或追溯重述后最近一个会计 年度利润总额、净利润或者扣除非经常性损益后的净利润孰低者为负值且营业收入低于3亿元"，公司股 票在2025年年度报告披露后可能被实施退市风险警示（在公司股票简称前加"*ST"）。敬请广大投资者 注意投资风险。 二、公司股票停牌情况及退市风险警示实施安排 如公司2025年年度经审计的扣除非经常性损益前后的净利润和扣除与主营业务无关的业务收入和不具备 商业实质的收入后的营业收入触及《股票上市规则》第9.3.2条第（一）项情形，公司股票将于2025年年 度报告披露日起开始停牌。披露日为非交易日的，于次一交易日起开始停牌。 根据《股票上市规则》规定，上海证券交易所在公司股票停牌之日后5个交易日内，根据规则规定，对 公司股票实施退市风险警示。公司将 ...

Core Viewpoint - The announcement details the resignation of two key personnel at Yuyuan Pharmaceutical Group Co., Ltd., including the election of a new employee representative director, ensuring compliance with legal regulations and maintaining board functionality [1][3]. Group 1: Resignation of Directors and Senior Management - Zhang Wei, the employee representative director, resigned for personal reasons but will remain with the company [1]. - Yang Lei, the deputy general manager, resigned due to work adjustments but will also continue to work at the company [1]. - Both resignations will not affect the normal operations of the company, as they have completed the necessary handover procedures [2]. Group 2: Election of Employee Representative Director - On February 13, 2026, Yang Lei was elected as the employee representative director for the third board of directors, with a term lasting until the end of the current board's term [3]. - Yang Lei meets all qualifications and conditions required by relevant laws and the company's articles of association to serve as a director [3]. - The number of directors who are also senior management and employee representative directors does not exceed half of the total board members, complying with legal and regulatory requirements [3].

Group 1 - The resignation of Mr. Liu Hongbo as a director of the company does not affect the minimum number of directors required by law, ensuring the normal operation of the board and management [2] - Mr. Liu has completed the necessary work handover according to company regulations, and the company will proceed with the legal process to elect a new director [2] - The company expresses gratitude for Mr. Liu's contributions during his tenure [2] Group 2 - The first extraordinary general meeting of shareholders for 2026 is scheduled for February 27, 2026 [5] - The State Development Investment Corporation, holding 41.82% of the shares, proposed a temporary motion to elect Mr. Xie Xiaobing as a non-independent director [6][7] - Mr. Xie Xiaobing, born in 1972, holds a bachelor's degree in economics and is a senior accountant, currently serving as a dedicated equity director at the State Development Investment Corporation [7] Group 3 - The meeting will take place at the Guotou Financial Building in Beijing, starting at 15:00 on February 27, 2026 [10] - Network voting will be available on the Shanghai Stock Exchange's system on the same day, with specific time slots for voting [11] - The original shareholding registration date for the meeting remains unchanged [12]

Core Viewpoint - Enwei Pharmaceutical's wholly-owned subsidiary, Sichuan Enwei Pharmaceutical Co., Ltd., has recently obtained a renewed Drug Production License, which is expected to positively impact the company's market product structure and financial performance [1][2]. Group 1: License Information - Sichuan Enwei has received a renewed Drug Production License valid until July 17, 2030, allowing the production of various forms of medication including ointments, granules, tablets, and capsules [1]. - The license number is 川20160226, and the company is located at 458, Section 3, Shuanghua Road, Shuangliu District, Chengdu, Sichuan Province [1]. Group 2: Product and Market Impact - The license change includes the authorization for Hunan Taiyang Pharmaceutical Co., Ltd. to produce the exclusive Chinese medicine product, Jiangnao Pain Relief Liniment, which is used for treating local pain and swelling caused by rheumatic arthritis [2]. - The production and market launch of Jiangnao Pain Relief Liniment are expected to optimize the company's product structure, meet market demand, and enhance revenue and profit metrics, contributing positively to the company's long-term operations [2].

Group 1 - The core point of the announcement is that Zhejiang Ruisheng Intelligent Technology Co., Ltd. plans to conduct daily related transactions in 2026, which are deemed necessary for the company's normal business operations and development [1][8] - The total expected amount for these related transactions is not to exceed 132 million RMB, which is approximately 19.2 million USD [3][4] - The related parties involved in these transactions include Ningbo Dongpurui Industrial Automation Co., Ltd., Ningbo Yimaisco Automation Technology Co., Ltd., Zhejiang Wuluo Smart City Technology Co., Ltd., and Ningbo Oushi Energy Saving Technology Co., Ltd. [3][5] Group 2 - The board of directors has unanimously approved the proposal for the expected related transactions, ensuring that these transactions will not adversely affect the company's financial status or operational results [2][8] - The transactions will be conducted based on fair market prices and will not harm the interests of the company or its shareholders, particularly minority shareholders [9][10] - The company emphasizes that its main business will not become dependent on related parties, thus maintaining its independence [10]

证券代码：600233 证券简称：圆通速递 公告编号：临2026-011 圆通速递股份有限公司 2026年1月快递业务主要经营数据公告 本公司董事局及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 圆通速递股份有限公司2026年1月快递业务主要经营数据如下： 2026年2月14日 ■ 上述数据未经审计，敬请广大投资者注意投资风险。 特此公告。 圆通速递股份有限公司 董事局 ...

关于2026年第一次临时股东会取消部分议案的公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容的 真实性、准确性和完整性依法承担法律责任。 一、股东会有关情况 1、股东会的类型和届次： 2026年第一次临时股东会 2、取消议案原因 证券代码：688382 证券简称：益方生物 公告编号：2026-008 益方生物科技（上海）股份有限公司 由于公司2025年限制性股票激励相关事项需统筹相关工作安排，基于综合评估和审慎考虑，经董事会薪 酬与考核委员会提议，2026年第一次临时股东会召集人公司董事会决定取消《关于〈益方生物科技（上 海）股份有限公司2025年限制性股票激励计划（草案）〉及其摘要的议案》《关于〈益方生物科技（上 海）股份有限公司2025年限制性股票激励计划实施考核管理办法〉的议案》《关于提请股东会授权董事 会办理公司2025年限制性股票激励计划相关事宜的议案》三项议案，上述三项议案暂不提交2026年第一 次临时股东会审议。 本次取消股东会议案符合《上市公司股东会规则》《上海证券交易所科创板股票上市规则》等相关法律 法规及《公司章程》的规定。 三、除了上述取消议 ...

公告送出日期：2026年2月14日 1 公告基本信息 特此公告。 东财基金管理有限公司 2 新任高级管理人员的相关信息 ■ 3 离任高级管理人员的相关信息 ■ 4 离任高级管理人员的相关信息 ■ 5 其他需要说明的事项 上述事项，已经东财基金管理有限公司董事会审议通过，并按相关规定进行备案。 ■ 2026年02月14日 ...